Garry Schwartz

3.3k total citations
40 papers, 2.0k citations indexed

About

Garry Schwartz is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Garry Schwartz has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Garry Schwartz's work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Treatment and Pharmacology (8 papers). Garry Schwartz is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Treatment and Pharmacology (8 papers). Garry Schwartz collaborates with scholars based in United States, Netherlands and Spain. Garry Schwartz's co-authors include Eric K. Rowinsky, Anthony W. Tolcher, Amita Patnaik, Lisa A. Hammond, L. A. Hammond, Andrew Goetz, Chris H. Takimoto, Ronald M. Bukowski, Robert A. Figlin and John A. Thompson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Garry Schwartz

40 papers receiving 1.9k citations

Peers

Countries citing papers authored by Garry Schwartz

Since Specialization

Citations

This map shows the geographic impact of Garry Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garry Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garry Schwartz more than expected).

Fields of papers citing papers by Garry Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garry Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garry Schwartz. The network helps show where Garry Schwartz may publish in the future.

Co-authorship network of co-authors of Garry Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Garry Schwartz. A scholar is included among the top collaborators of Garry Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garry Schwartz. Garry Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A case study of 10 patients administered HBOC‐201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option 2020 ·Transfusion ·Marc Zumberg, Jed B. Gorlin, Elizabeth A. Griffiths, Garry Schwartz, Bradley S. Fletcher, Katherine Walsh, (unknown), (unknown), Mauricio Lynn, Aryeh Shander	8
2	Use of the blood substitute HBOC‐201 in critically ill patients during sickle crisis: a three‐case series 2017 ·Transfusion ·Jonathan M. Davis, (unknown), (unknown), Garry Schwartz, Margaret Block, (unknown), Mark Tidswell, Ernest DiNino	19
3	Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity? 2014 ·Journal of Clinical Oncology ·Daniel L. Hertz, Anna C. Snavely, James P. Evans, Joseph G. Ibrahim, Steven M. Anderson, Kenneth J. Friedman, Karen E. Weck, Peter Rubin, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R. Carrizosa, Steven Corso, Garry Schwartz, Jeffrey Peppercorn, Mark L. Graham, (unknown), Howard L. McLeod, Lisa A. Carey, William Irvin	3
4	A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·Thomas E. Stinchcombe, Amy H. Peterman, Carrie B. Lee, Dominic T. Moore, Jennifer L. Beaumont, Daniel S. Bradford, (unknown), Mark Taylor, Jeffrey M. Crane, Garry Schwartz, Thomas A. Hensing, Edwin McElroy, Harvey B. Niell, Harry Harper, (unknown), Mark A. Socinski	30
5	Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer 2011 ·British Journal of Cancer ·Alain C. Mita, K. Papadopoulos, Maja J.A. de Jonge, Garry Schwartz, Jaap Verweij, Monica Mita, Alejandro D. Ricart, (unknown), Anthony W. Tolcher, Lincoln C. Wood, (unknown), Marta Hamilton, Kenneth K. Iwata, Bret Wacker, Karsten Witt, Eric K. Rowinsky	36
6	Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study 2008 ·Clinical Cancer Research ·Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding	130
7	P3-115: Erlotinib (Tarcevar) “dosing–to–rash”: characterization of skin toxicity from a pilot phase II intra–patient dose–escalation study of E in previously treated patients with advanced non–small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Alain C. Mita, Maja J. De Jonge, Jaap Verweij, Kyriakos P. Papadopoulos, Garry Schwartz, Monica Mita, Bret Wacker, Maureen G. Conlan, Sean P. McCarthy, James G. Krueger	4
8	Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies 2007 ·Journal of Clinical Oncology ·Quincy S. Chu, Garry Schwartz, Johann S. de Bono, Deborah A. Smith, Kevin M. Koch, M. Versola, Lini Pandite, Nikita Arya, (unknown), Ronald A. Fleming, Peter Ho, Eric K. Rowinsky	48
9	A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas 2007 ·Investigational New Drugs ·Quincy Chu, Bahram Forouzesh, Samira Syed, Monica Mita, Garry Schwartz, (unknown), (unknown), Eric K. Rowinsky	46
10	A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer 2005 ·Annals of Oncology ·Monica Mita, (unknown), Eric K. Rowinsky, John G. Kuhn, Garry Schwartz, L. A. Hammond, Amita Patnaik, I‐Tien Yeh, Elżbieta Izbicka, (unknown), Anthony W. Tolcher	36
11	A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer 2005 ·Clinical Cancer Research ·Anthony W. Tolcher, Kim Chi, John G. Kuhn, Martin Gleave, Amita Patnaik, Chris H. Takimoto, Garry Schwartz, Ian M. Thompson, (unknown), Susan D’Aloisio, Nevin Murray, Stanley R. Frankel, Elżbieta Izbicka, Eric K. Rowinsky	123
12	A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies 2004 ·Investigational New Drugs ·Garry Schwartz, Christopher B. Jones, Mitchell Garrison, Amita Patnaik, Chris H. Takimoto, (unknown), Michael Skinner, Anthony W. Tolcher, Eric K. Rowinsky	2
13	Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors 2004 ·Journal of Clinical Oncology ·Garry Schwartz, Quincy Chu, L. A. Hammond, (unknown), (unknown), M. Versola, Kevin M. Koch, Lini Pandite, (unknown), Eric K. Rowinsky	20
14	Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Kenneth A. Foon, (unknown), Louis M. Weiner, Arie S. Belldegrun, Robert A. Figlin, Jeffrey Crawford, Eric K. Rowinsky, Janice P. Dutcher, Nicholas J. Vogelzang, (unknown), John A. Thompson, Garry Schwartz, Ronald M. Bukowski, Lorin Roskos, Gisela Schwab	177
15	Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules 2003 ·British Journal of Cancer ·Anthony W. Tolcher, Stanton L. Gerson, Denis Lairon, Christiane Geyer, L. A. Hammond, Amita Patnaik, Andrew Goetz, Garry Schwartz, Tammy L. Edwards, Larisa Reyderman, Paul Statkevich, David L. Cutler, Eric K. Rowinsky	285
16	A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies 2003 ·Annals of Oncology ·Garry Schwartz, Amita Patnaik, L. A. Hammond, Jinee Rizzo, (unknown), Daniel D. Von Hoff, Eric K. Rowinsky	36
17	A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. 2003 ·PubMed ·Desirée Hao, Lisa A. Hammond, Sabine Eckhardt, Amita Patnaik, Chris H. Takimoto, Garry Schwartz, Andrew Goetz, Anthony W. Tolcher, (unknown), (unknown), Jon I. Williams, Kenneth J. Holroyd, Eric K. Rowinsky	36
18	A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. 2003 ·PubMed ·Mitchell Garrison, Lisa A. Hammond, Charles E. Geyer, Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, José A. Figueroa, Murray P. Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky	14
19	Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies 2000 ·Annals of Oncology ·(unknown), Herbert I. Hurwitz, George Wilding, Darrel P. Cohen, (unknown), Garry Schwartz, (unknown), William P. Petros, (unknown), (unknown), (unknown), Ronald Drengler, (unknown), Eric K. Rowinsky	12
20	DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies 2000 ·Journal of Clinical Oncology ·Eric K. Rowinsky, Thomas R. Johnson, Charles E. Geyer, Lisa A. Hammond, S. Gail Eckhardt, Ronald Drengler, Leslie Smetzer, John Coyle, Jinee Rizzo, Garry Schwartz, Anthony W. Tolcher, Daniel D. Von Hoff, Robert L. De Jager	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact